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Abstract
Background: To investigate the relationship between oxysterols and mild cognitive impairment (MCI) in a matched
case–control study.
Methods: The plasma levels of four oxysterols, 27–hydroxycholesterol (27–OHC), 24S–hydroxycholesterol (24S–OHC),
7α–hydroxycholesterol (7α–OHC) and 7β–hydroxycholesterol (7β–OHC), were analyzed by High Performance Liquid
Chromatography–Mass Spectrometry (HPLC–MS) and compared between 70 MCI patients and 140 matched controls
with normal cognition. The odds ratio (OR) was calculated using logistic analyses to assess the association between
oxysterols and MCI.
Results: Compared with controls with normal cognition, plasma level of 27–OHC was significantly higher in MCI
patients. Logistic analyses suggested high plasma level of 27–OHC was significantly associated with MCI even after
multivariate adjustment (OR = 2.86, 95 % CI: 1.52 ~ 5.37).
Conclusions: Our findings suggested that the increased plasma level of 27-OHC was associated with MCI,
suggesting high plasma levels of 27-OHC may pay an important role in the development of MCI.
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Background
Alzheimer’s disease (AD) is the most commonly recog-
nized cause of dementia by memory loss and other intel-
lectual symptoms serious enough to affect daily life in the
elderly [1]. It contributes to premature death of elders
after being diagnosed for 3 to 9 years [2]. MCI is the pre–
clinical stage of AD with gradual cognitive decline but no
influence on daily life activities. It is accepted that early
intervention in MCI including decreasing the risk factors
is useful and therefore many studies have focused on this
stage [3].
Substantial epidemiological and molecular evidence has
indicated that hypercholesterolemia is an important risk
factor for neurodegenerative diseases [4]. However, clinical
studies by using statins to lower the cholesterol for pre-
ventive and therapeutic management of neurodegeneration
did not show the effects [5]. In addition, cholesterol in the
blood cannot pass the blood brain barrier into central ner-
vous system (CNS) [6]. The above facts cannot support the
role of high plasma level of cholesterol in AD or MCI.
Oxysterols including 27–OHC, 24S–OHC, 7α–OHC
and 7β–OHC are the oxidized derivatives of cholesterol,
which can not only pass the blood brain barrier [7] but
also have cytotoxic and pro-apoptotic properties [8, 9].
27–OHC is the most abundant circulating oxysterol
mainly produced in the liver [10]. Previous studies have
also demonstrated an influx of the 27-OHC from the circu-
lation into the brain [11]. Despite the fact that cholesterol
cannot pass the blood–brain barrier, hypercholesterolemia
is linked to an increased risk of neurodegenerative condi-
tions including AD [12, 13], in particular in midlife [14].
Since there is a close correlation between circulating chol-
esterol and 27-OHC [15], hypercholesterolemia seems to
result in an increased uptake of 27-OHC. Meanwhile,
Heverin et al. [16] has demonstrated that treatment of
mice with dietary cholesterol causes significant memory
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impairment and 27-OHC mediates the negative effects
of dietary cholesterol on cognition. Therefore, there is
possibility that 27-OHC is linking the excessive diet chol-
esterol or hypercholesterolemia and neurodegenerative
conditions. A recent study showed a significant accumula-
tion of 27–OHC in the brain of patients with AD [17]. In
addition, one animal study showed the level of 27–OHC
in 12–month–old rats is higher than that in 8–month–old
rats, suggesting the accumulation of 27–OHC in the brain
with age [18].
Despite the accumulated evidence about the relation-
ship of oxysterols with neurodegenerative diseases such
as AD, there are no direct data from humans to evaluate
the relationship between oxysterols and MCI. The aim
of this study was to evaluate plasma levels of 27–OHC,
24S–OHC, 7α–OHC and 7β–OHC in the elderly with
and without MCI and attempt to establish potential
relationships between these oxysterols and cognitive
function.
Methods
Subjects and cognitive assessment
Seventy hospitalized subjects diagnosed as MCI and 140
controls with normal cognition were recruited from
Xuan Wu Hospital in Beijing, China. The study design
was ethically approved by the Ethics Committee of Capital
Medical University (2013SY35). The process was explained
for all subjects before the written informed consent was
obtained. Controls were age- (±5 years), sex- and educa-
tion- matched with MCI patients. The subjects with the
history of a cerebrovascular event, malignant tumor and
psychiatric illness or other neurological disease and statin
or hypnotic sedative drugs abuse were excluded from the
study. Cognitive function was evaluated by professional
interviewers using the Mini–Mental State Examination
(MMSE) [19] and Montreal Cognitive Assessment
(MoCA) [20]. MMSE is commonly used to screen for de-
mentia but insensitive to MCI while the MoCA was spe-
cially developed for detection of MCI [20]. All MCI
patients should primarily satisfy the criteria of MCI includ-
ing the following: (1) normal general cognitive function
and absence of dementia that is sufficient to satisfy MMSE
score of >19 for illiterate individuals, >22 for individuals
with 1 to 6 years of education and >26 for individuals with
7 or more years of education; (2) mild impairment of cog-
nitive functioning evaluated by MoCA score of ≤14 for
illiterate individuals, ≤19 for individuals with 1 to 6 years
of education and ≤24 for individuals with 7 or more years
of education. If the subjects meet the above MCI criteria,
they will visit a neurologist to make the final diagnosis.
Demographic, clinical and anthropometric assessment
Demographics (age, gender, education, weight and height),
lifestyle habits (current smoking status and drinking
status), history of hypertension, coronary heart disease,
diabetes and cerebrovascular disease were collected by
self–reported questionnaire. Body mass index (BMI) was
calculated as weight (kg)/height2 (m2). Current smoking
status and drinking status were binary variables. Subjects
were classified as smokers if they reported smoking three
or more cigarettes a week for more than six months be-
fore enrollment and non-smokers if their cigarettes con-
sumption was lower than this. Drinkers were identified by
reporting alcohol consumption three or more times a
week for more than six months before enrollment and
non-drinkers lower than this.
Laboratory measurements
The 0.6 mL tubes containing EDTA anticoagulant were
used to collect fasting venous blood samples. The plasma
samples were harvested after centrifugation at 3000 rpm
for 10 min at 4 °C and stored frozen at −80 °C until
measurement. The levels of plasma triglycerides (TG),
total cholesterol (TC), high–density lipoprotein choles-
terol (HDL–C), low-density lipoprotein cholesterol
(LDL–C) and fasting blood glucose (FBG) were mea-
sured on a HITACHI 7600 analyzer. Aβ1-40 and Aβ1-
42 plasma levels were evaluated by ELISA kit.
Plasma levels of oxysterols were measured using High
Performance Liquid Chromatography–Mass Spectrom-
etry (HPLC–MS) as described by Ines Burkard, et al.
[21] with slight modifications. Briefly, 0.1 mL of plasma
sample was transferred to a screw–capped vial and
100 ng of 19–hydroxycholesterol (19–OHC) was also
added to the vial serving as internal standard. Alkaline
hydrolysis was performed at 50 °C water bath for 2 h
after adding 1.5 mL of 1 M ethanolic sodium hydroxide.
Phosphoric acid (50 %) and 1 mL of phosphate buffer
were added to the samples to adjust pH to 7. Super-
natant was harvested after the centrifugation at 1000 g
for 5 min and then applied to the C18 cartridges for
solid–phase extraction. The eluted substances were dried
at 30 °C and dissolved in 100 mL of methanol for future
test. HPLC with an Angilent G1312B HPLC Pump and
an Angilent C18 column (0.35 μm bead size; 4.6 ×
250 mm) were used for the measurement of oxysterols.
Quantification of oxysterols was performed using the
multiple reaction monitoring (MRM) mode.
Statistical analysis
The data were expressed by means ± standard deviations
for normally distributed continuous variables, medians
(interquartile ranges) for non–normally distributed
continuous variables and frequencies (percentages) for
categorical variables. Independent t–test and Mann
Whitney U test were used for continuous variables and
Chi–square test for categorical variables to compare dif-
ferences between MCI and control groups. 27–OHC,
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24S–OHC, 7α–OHC and 7β–OHC levels were classified
into high and low levels by their medians. Univariate
conditional logistic regression was used to evaluate the
association between four oxysterols (treated as categor-
ical variables) and MCI risk. Multivariate analysis was
used to adjust demographic, clinical and anthropometric
characteristics. Spearman rank correlation test was cal-
culated to assess correlation coefficients. And P < 0.05
was considered statistically significant. All of the statis-
tical analyses were performed using SPSS (version 18.0).
Results
This study included 70 MCI patients (35 men and 35
women) and 140 controls with normal cognitive state
(70 men and 70 women). Demographic and clinical
characteristics of all the subjects were summarized in
Table 1. Drinkers (P = 0.03), MoCA scores (P < 0.01),
Aβ1-40 (P < 0.01) and Aβ1-42 (P < 0.01) were observed
with significant differences between MCI and control
group.
The plasma levels of four oxysterols were present in
Table 2. There was significant difference between the two
groups regarding the plasma 27–OHC levels but no sig-
nificant differences in 24S–OHC, 7α–OHC and 7β–OHC
levels.
Table 3 using univariate analysis showed that only
high plasma level of 27-OHC was associated with MCI
(OR = 3.21, 95 % CI: 1.76 ~ 5.85). Four oxysterols were
classified into high and low levels by their medians.
Table 4 showed the significant association between
high plasma level of 27-OHC and MCI persisted even
after adjustment (OR = 2.86, 95 % CI: 1.52 ~ 5.37).
Spearman correlation analyses showed that the plasma
level of 27-OHC was positively correlated with that of
Aβ1-40 and Aβ1-42 and negatively correlated with MoCA
scores (Fig. 1a–c).
Table 1 Demographic and clinical characteristics of MCI patients and controls
MCI Controls P value
(n = 70) (n = 140)
Demographic and risk factors
Age (y) 59 (61–72) 60 (62–69) –
Male, % 50.0 50.0 –
Education (y) –
≤ 9, (%) 44.3 44.3
9 ~ 12, (%) 25.7 25.7
≥ 12, (%) 30.0 30.0
Smokers, % 32.9 22.9 0.12a
Drinkers, % 22.9 37.9 0.03a
Hypertension, % 41.4 41.4 1.00a
Coronary Heart Disease, % 7.1 8.6 0.72a
Diabetes, % 20.0 12.1 0.13a
Cerebrovascular Disease, % 2.9 2.9 1.00a
BMI (kg/m2) 24.42 ±2.53 25.25 ±3.78 0.10b
MCI screening
MMSE scores 28 (27–29) 28 (27–30) 0.07 c
MoCA scores 22 (19–23) 26 (25–28) <0.01c
Laboratory
FBG (mmol/L) 5.58 (5.20–6.25) 5.54 (5.09–6.14) 0.38c
TG (mmol/L) 1.38 (0.97–2.03) 1.41 (1.01–2.07) 0.69c
HDL-C (mmol/L) 1.4 (1.18–1.60) 1.4 (1.10–1.53) 0.71c
LDL-C (mmol/L) 2.57 ±0.75 2.76 ±0.74 0.09b
TC (mmol/L) 4.56 ±1.00 4.73 ±0.85 0.20b
Aβ1-40 (pg/mL) 992.08 ±208.92 589.08 ±214.39 <0.01b
Aβ1-42 (pg/mL) 795.01 ±177.43 451.54 ±209.08 <0.01b
a Data presented as frequencies (percentages) were compared between 2 groups by using Chi-square test
b Data presented as means ± standard deviations were compared between 2 groups by using the Student t–test
c Data presented as medians (interquartile ranges) were compared between 2groups by using the Mann Whitney U test
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Discussion
In these four oxysterols, 27–OHC is the major choles-
terol metabolite in the circulation and mainly produced
from cholesterol in periphery and synthesized in almost
all cells by the cytochrome P-450 enzyme CYP27A1 lo-
cated in the inner mitochondrial membranes. A signifi-
cant association between high plasma level of 27-OHC
and MCI was observed in this study. Our results were in
accordance with the previous studies that described 27–
OHC level in blood was negatively associated with cog-
nitive performance in aging population and was signifi-
cantly higher in AD patients [22, 23]. However, subjects
with neurological diseases, such as AD or other types of
dementia, were ruled out by exclusion criteria in our
study for more reliable results prior to medication.
There was also a negative correlation between plasma
27-OHC level and MoCA scores (r = − 0.269, P = 0.001).
The negative correlation indicates that 27-OHC produc-
tion in the blood is expected to increase with severity of
cognitive impairment.
Previous research has indicated that subjects with high
Aβ levels showed increased cognitive impairment [24].
Marwarhaet al [25] has found that 27-OHC induced 3-
fold increase in Aβ1-42 and 1.5-fold increase in Aβ1-40
levels in the organotypic slices from rabbits. Moreover,
Prasanthiet al [26] treated human neuroblastoma SH-
SY5Y cells with 27-OHC and found a substantial in-
crease in Aβ1-42 levels compared to untreated cells.
Our study has also shown MCI patients had higher
plasma Aβ1-40 and Aβ1-42 levels than controls with
normal cognition (P <0.01). Simultaneously, a good posi-
tive correlation between plasma levels of Aβ1-42 and
27-OHC (r = 0.269, P = 0.005) and a weak but signifi-
cant correlation of plasma 27-OHC with Aβ1-40 levels
(r = 0.192, P = 0.048) were also observed, supporting the
hypothesis that 27-OHC may enhance circulating amyl-
oid production and increase the risk of cognitive
impairment.
Despite that, studies analyzing the associations be-
tween plasma 27–OHC level and cognitive decline
yielded conflicting results. Timothy M. Hughes et al.
[27] recently found that the increase of plasma 27–OHC
levels was related to cerebrovascular disease prior to
cognitive decline over many years of follow–up. How-
ever, it lacked MRI results for cerebrovascular disease
when the volunteers were diagnosed of AD or MCI in
follow–up. Thus, the question arises whether cerebro-
vascular disease is the injury factor for cognitive status.
In addition, a case–control study has shown that the ra-
tio of 27–OHC to total circulating cholesterol (27–
OHC/Chol) level is lower in AD and MCI patients than
that in controls [28]. There is possibility that oxysterols
and cholesterol compete for space within the lipopro-
teins and they have different scales on space within the
lipoprotein, absolute levels of plasma 27–OHC may be
higher in MCI compared to controls despite of the de-
crease of 27–OHC/Chol.
On the other hand, in the brain, cholesterol is re-
moved by conversion to 24S–OHC via CYP46A1 en-
zyme, which is primarily expressed in neurons. We
found no significant difference in 24S–OHC level in
plasma between MCI patients and control group. In
contrast to the former research, they observed signifi-
cantly elevated or declined plasma levels of 24S–OHC in
AD, vascular disease (VaD) and MCI participants [29,
30]. These conflicting findings may result from study
population with different time after being diagnosed
Table 2 Plasma levels of four oxysterols in MCI patients and controls (ng/mL)
Oxysterol 27–OHC 24S–OHC 7α–OHC 7β–OHC
MCI 74.23 (55.34–99.50) 44.55 (28.91–60.04) 47.48 (31.89–65.47) 51.20 (38.84–72.13)
(n = 70)
Controls 56.48 (43.71–82.13) 44.69 (35.81–65.60) 45.57 (31.10–63.78) 52.07 (37.47–75.86)
(n = 140)
P value <0.01 a 0.69 a 0.68 a 0.87 a
a Data presented as medians (interquartile ranges) were compared between 2 groups by using the Mann Whitney U test
Table 3 Odds ratio of MCI for oxysterols in univariate regression
analysis
Oxysterols Odds ratio and 95 % CI P value
Low level High level
27-OHC Ref 3.21 (1.76–5.85) <0.01
24S-OHC Ref 0.93 (0.51–1.68) 0.80
7α-OHC Ref 1.26 (0.66–2.41) 0.48
7β-OHC Ref 0.89 (0.46–1.73) 0.74
The plasma levels of 27–OHC, 24S–OHC, 7α–OHC and 7β–OHC were classified
into high and low levels by their medians
Table 4 Results of univariate and multivariate regression
analysis for 27-OHC
Model Odds ratio and 95 % confidence interval P value
Low 27–OHC High 27–OHC
Unadjusted Ref 3.21 (1.76–5.85) <0.01
Adjusteda Ref 2.86 (1.52–5.37) <0.01
aAdjusted for demographic and risk factors
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with MCI. The late MCI patients with the loss of neur-
onal cells had decreased level of 24S–OHC whereas the
early MCI patients were characterized by the increase of
24S–OHC probably as a consequence of the released
cholesterol caused by the myelin disruption [31].
Unlike 27–OHC and 24S–OHC, 7β–OHC is generated
by non–enzymatic oxidation whereas 7α–OHC is gener-
ated by both non–enzymatic and enzymatic oxidation that
is catalyzed by CYP7A1 [32]. The effects of 7α–OHC and
7β–OHC on cognitive function are less known. MCI falls
in between normal forgetfulness and AD. It is accepted
that early intervention in MCI including decreasing the
risk factors is useful. Our findings has offered some valid
epidemiological evidence to reveal the role of 27-OHC in
the pathogenesis of MCI, which may provide new insights
into the prevention of AD. Some experiments in cell cul-
tures and animals have suggested increased levels of 27-
OHC may trigger or accelerate progression of AD or MCI
through a variety of mechanisms. However, efforts to find
out the role of 27-OHC in AD or MCI are still necessary
by further human studies. The strengths of our study was
a matched case–control study after adjustment for con-
founders and based on standardized epidemiological
methods. Additionally, we enrolled MCI patients without
medication as the target population in order to more dir-
ectly investigate the relationship with risk factors than AD
patients and take preventive measures in the preclinical
stage of AD. However, it was a case–control study that
can not establish the timeline of exposure to disease out-
come, prospective cohort studies are also needed to fur-
ther evaluate the role of oxysterols in AD or MCI.
Conclusions
In conclusion, our findings suggested plasma level of
27-OHC was significantly higher in MCI patients than
controls with normal cognition and the increased
plasma level of 27-OHC was significantly associated
with MCI. Prospective cohort studies and experiments
in vitro are needed to further evaluate the potential role
of 27-OHC and other oxysterols in involvement in AD
or MCI.
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